|
|
Clinical trials supported by AFM
At the present time the AFM is contributing financially to 34 clinical trials – either ongoing or in preparation. They concern both neuromuscular and non-neuromuscular diseases : - neuromuscular diseases - neurological or neurodegenerative diseases: leukodystrophies (2 different forms), Huntington disease, Friedreich ataxia and San Filippo diseases (2 different types) - blood diseases: drepanocytosis, beta-thalassemia and porphyria - immune deficiencies: ADA and WASP - skin disease: epidermolysis bullosa (2 different forms) - eye disease: Leber Amaurosis - ageing disease: progeria - myocardial infarction
These trials are distributed between : - gene therapy (50%) to correct genetic mutations and produce missing or deficient proteins - cell therapy to regenerate diseased tissue (20%) - classic pharmacology (30%) with molecules already used for other diseases but likely to be beneficial for neuromuscular diseases, or new molecules likely to attack directly the cause or the consequences of genetic damage.
|